{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T14:30:41Z","timestamp":1791729041234,"version":"4.3.4"},"reference-count":22,"publisher":"Wiley","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Case Reports in Oncological Medicine"],"published-print":{"date-parts":[[2018]]},"abstract":"<jats:p><jats:italic>Background<\/jats:italic>. Patients with autoimmune diseases were not evaluated in clinical trials with immune checkpoint inhibitors (ICIs), since a history of immune disorders, such as Guillain\u2013Barr\u00e9 syndrome (GBS) and psoriasis, is one of the major risk factors for the development of immune-related adverse events (irAEs). This risk cannot be defined; therefore, physicians are called to manage these patients in clinical practice. <jats:italic>Case Report<\/jats:italic>. We report the case of a 62-year-old male patient affected by metastatic melanoma, with a history of GBS and psoriasis, and treated with sequential ipilimumab, pembrolizumab, and nivolumab, without significant toxicities. <jats:italic>Conclusion<\/jats:italic>. This case report supports that although a history of immune disorders is one of the major risk factors for development of irAEs, in some patients, it could be possible to safely administer sequential treatments with ICIs. A proper decision should be made, considering therapeutic options, disease-related risks, and those related to a recurrence of preexisting autoimmune disorders.<\/jats:p>","DOI":"10.1155\/2018\/2783917","type":"journal-article","created":{"date-parts":[[2018,3,8]],"date-time":"2018-03-08T18:30:38Z","timestamp":1520533838000},"page":"1-4","source":"Crossref","is-referenced-by-count":4,"title":["Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient with Metastatic Melanoma, Psoriasis, and a Previous Guillain\u2013Barr\u00e9 Syndrome"],"prefix":"10.1155","volume":"2018","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1209-5735","authenticated-orcid":true,"given":"Alessio","family":"Cortellini","sequence":"first","affiliation":[{"name":"Medical Oncology Unit, St. Salvatore Hospital, L\u2019Aquila, Italy"},{"name":"Department of Biotechnological and Applied Clinical Sciences, University of L\u2019Aquila, L\u2019Aquila, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Parisi","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, St. Salvatore Hospital, L\u2019Aquila, Italy"},{"name":"Department of Biotechnological and Applied Clinical Sciences, University of L\u2019Aquila, L\u2019Aquila, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Concetta","family":"Fargnoli","sequence":"additional","affiliation":[{"name":"Department of Biotechnological and Applied Clinical Sciences, University of L\u2019Aquila, L\u2019Aquila, Italy"},{"name":"Oncological Dermatology Unit, St. Salvatore Hospital, L\u2019Aquila, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Cannita","sequence":"additional","affiliation":[{"name":"Department of Biotechnological and Applied Clinical Sciences, University of L\u2019Aquila, L\u2019Aquila, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4724-6297","authenticated-orcid":true,"given":"Azzurra","family":"Irelli","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, St. Salvatore Hospital, L\u2019Aquila, Italy"},{"name":"Department of Biotechnological and Applied Clinical Sciences, University of L\u2019Aquila, L\u2019Aquila, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampiero","family":"Porzio","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, St. Salvatore Hospital, L\u2019Aquila, Italy"},{"name":"Department of Biotechnological and Applied Clinical Sciences, University of L\u2019Aquila, L\u2019Aquila, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Martinazzo","sequence":"additional","affiliation":[{"name":"Department of Neurophysiopathology, St. Salvatore Hospital, L\u2019Aquila, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Ficorella","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, St. Salvatore Hospital, L\u2019Aquila, Italy"},{"name":"Department of Biotechnological and Applied Clinical Sciences, University of L\u2019Aquila, L\u2019Aquila, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv623"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw378.31"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1003466"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1504627"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1611299"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr028"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2012-000447"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1097\/cji.0b013e31827807dd"},{"key":"9","first-page":"A6185","volume":"189","year":"2014","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1097\/cji.0000000000000167"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2014.121"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1412082"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1504030"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(15)01281-7"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1200694"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2212"},{"key":"17","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13336"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.0249"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.5210"},{"key":"20","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.4368"},{"key":"21","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw443"},{"key":"22","year":"2010"}],"container-title":["Case Reports in Oncological Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/crionm\/2018\/2783917.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/crionm\/2018\/2783917.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/crionm\/2018\/2783917.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,3,8]],"date-time":"2018-03-08T18:30:39Z","timestamp":1520533839000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.hindawi.com\/journals\/crionm\/2018\/2783917\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":22,"alternative-id":["2783917","2783917"],"URL":"https:\/\/doi.org\/10.1155\/2018\/2783917","relation":{},"ISSN":["2090-6706","2090-6714"],"issn-type":[{"value":"2090-6706","type":"print"},{"value":"2090-6714","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}